Zobrazeno 1 - 10
of 221
pro vyhledávání: '"azvudine"'
Autor:
Huaiya Xie, Yaqi Wang, Yan Xu, Luo Wang, Junping Fan, Siqi Pan, Chuan Shi, Xiaoyan Liu, Xiaoxing Gao, Xiaobei Guo, Siyuan Yu, Jia Liu, Dongming Zhang, Yanli Yang, Hong Zhang, Jinglan Wang, Aohua Wu, Xueqi Liu, Jihai Liu, Huadong Zhu, Xiang Zhou, Xinlun Tian, Mengzhao Wang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 pat
Externí odkaz:
https://doaj.org/article/d88b3e55da7d4fe7873f45189db8222e
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 4317-4325 (2024)
Siqin Zhang,1,* Songsong Tan,1,* Bin Yang,2 Yaoyao Wu,3 Guohang Yuan,3 Fengjiao Chen,4 Lin Liu3,5 1Department of Endocrinology and Metabolism, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, 550002, People’s Republic of China; 2De
Externí odkaz:
https://doaj.org/article/9160545218554d61a0bcff3d87ad48ea
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 3967-3978 (2024)
Ximiao Yu,1,* Ruiqi Luo,2,* Guijuan Xie,2 Jiali Ji,3,4 Jiehong Wang,1 Xiyue Li,3 Xiaojun Qian,2 Xun Wang1,2,5 1Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu Province, People’s Republic of China; 2Department of Pulmonary and Cr
Externí odkaz:
https://doaj.org/article/d8e82d493dc54688b5b23018834f80fe
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 7, Pp 3140-3154 (2024)
Thymus is the important immune organ, responsible for T cell development and differentiation. The lower circulating T counts have been observed in patients who died from COVID-19 compared with survivors. Azvudine, also known as FNC, is a thymus-homin
Externí odkaz:
https://doaj.org/article/6dae7bb2a4a744aaba39f7163fa9d4a9
Autor:
Wenfang Yuan, Yongmei Liu, Haoting Zhan, Feng Wei, Qian Zhang, Huixia Gao, Huimin Yan, Tao Huang, Yongzhe Li, Erhei Dai
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
ObjectiveThe aim of this study was to explore the clinical characteristics of patients infected with different Omicron subvariants presenting non-severe disease, evaluate the safety and efficacy of Azvudine for treatment of COVID-19, in order to broa
Externí odkaz:
https://doaj.org/article/9cbe41a4c67d4de78f5ebbbf626da362
Publikováno v:
Journal of Infection and Public Health, Vol 17, Iss 12, Pp 102583- (2024)
Background: COVID-19 pneumonia has spread across China and globally since late 2019, becoming a pandemic. Its extremely contagious nature as well as high morbidity and mortality rates have attracted widespread attention globally. For the treatment of
Externí odkaz:
https://doaj.org/article/82a6fa43e98948c89581950ca286dbcd
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundLittle is known about immunophenotyping characteristics and clinical outcomes of COVID-19 patients treated with azvudine during the Omicron variant surge.MethodsThis study enrolled patients diagnosed with COVID-19 from December 2022 to Febr
Externí odkaz:
https://doaj.org/article/4b1bfd7bed6e409ead900555d4ebf3e6
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 14 (2024)
BackgroundAzvudine (AZV), the first Chinese oral anti-coronavirus disease 2019 (COVID-19) drug, has shown substantial clinical benefits to viral clearance and prognosis in patients with mild and common COVID-19. However, there is no evidence in sever
Externí odkaz:
https://doaj.org/article/47e31c1086104124b7f6edd04743bd6f
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 14 (2024)
BackgroundAzvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further researc
Externí odkaz:
https://doaj.org/article/2ca0bba0526c41a2917078c0c43a63bf
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 7, Pp n/a-n/a (2024)
ABSTRACT Background Azvudine (FNC) is a novel small molecule antiviral drug for treating COVID‐19 that is available only on the Chinese market. Despite being recommended for treating COVID‐19 by the Chinese guidelines, its efficacy and safety are
Externí odkaz:
https://doaj.org/article/18d9409ec7434cb8a82cb3a8439c8253